Exploring a Non-Invasive Investigational Therapy for Dry Age-Related Macular Degeneration!

About the Study

Age-Related Macular Degeneration (AMD) is a common cause of the loss of eyesight. Over 80% of people diagnosed with AMD have dry (nonexudative) age-related macular degeneration. There is currently no available treatment for dry AMD. However, taking supplements may hopefully slow the progression of this condition.

An eye health research study is being conducted across various sites in the United States. This research study seeks to explore a new potential non-invasive therapy for dry (nonexudative) age-related macular degeneration (AMD). The study will also evaluate the therapy’s effect on vision and quality of life. If this potential therapy is deemed safe and effective, it could improve the lives of millions of adults. 

Are you interested in joining this study? See if you meet the eligibility criteria! 

Why Participate? 

  • Participants may receive several months of treatment at no cost. This treatment may or may not help to improve vision on a short-term basis.
  • Participants may or may not experience improvements to their dry AMD. 
  • Participants will be contributing valuable information that may benefit those with dry AMD in the future.
  • Participants will be compensated for participating in this study and transportation may be provided if needed.
  • Participants will be helping to advance eye health research.

Your Rights

  • If you decide to participate in the study and later feel that you no longer wish to be part of it, you can withdraw at any time.
  • Any information that you provide will be kept strictly confidential, except as required by law.
  • Qualified health professionals will monitor your health as it relates to the study.

Who Can Participate?

  • Men and women aged 50 years old or older who have been diagnosed with dry (nonexudative) age-related macular degeneration (AMD)
  • Must have vision no worse than 20/200 or legally blind
  • Must not be taking a prescription blood thinner
  • Must not be a current smoker or history of heavy smoking more than 1/2 pack per day in the last 10 years
  • Must not have diabetic retinopathy or wet (exudative) age-related macular degeneration in either eye
  • Must be able to attend 14 study visits at the research site over approximately 12 ½ months

More Study Details 

The study team will explain the research study in its entirety but some details are:

  • Participation in this study involves an initial 5-day treatment course and 2 maintenance treatment visits.
  • This potential therapy is transpalpebral microcurrent electrical stimulation (MCS) therapy. It is non-invasive and intended for the treatment of dry age-related macular degeneration.

 

This research study is taking place in several locations. To see if there is a research site near you, please see below.

 


Research Site: Associated Retina Consultants
Location: 1750 E. Glendale Ave., Phoenix, AZ 85020
Lead Researcher: Benjamin Bakall, MD, PhD

 


Research Site: Cumberland Valley Retina Consultants
Location: 414 Epic Dr. Chambersburg, PA 17201
Lead Researcher: Allen Hu, MD

This study has been reviewed by an Institutional Review Board.

What’s Next?

  1. Click the link to enter your contact details and take the study questionnaire.
  2. If eligible, a member of the research team will contact you to discuss the study and answer any questions you may have.
Click Here to Check Your Eligibility for This Study